A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Klarman doubled down earlier this year, and won right to pursue lawsuit in Nevada courts. Importantly, they didn't win the lawsuit yet, but the court deemed it valid: a small step in a process that could lead to tremendous upside. And in the event that this doesn't happen there appears to be enought value in their existing business (even though it is in terminal decline) to support their stock price. I am very early in my research, but this is my general understanding of the investment case so far.